Continuous monitors track blood glucose levels 24 hours a day through a sensor just under your skin, replacing finger-prick testing. They are widely funded and used overseas. The monitors alert users ...

Abbott Laboratories has reported sales of $10.6bn for the third quarter (Q3) of 2024, as against $10.4bn in Q2 2024, with ...

Increasing diabetes care awareness, wider insurance coverage and preference for devices that do not need finger pricks have ...

High-deductible health plans can offer expanded benefits for contraception, diabetes, and breast cancer services to enrollees ...

GEORGIA AVENUE, WA, UNITED STATES, October 17, 2024 /EINPresswire / -- The latest release from Vantage <a target=_blank href= ...

Abbott Laboratories (ABT) reports robust sales growth in key segments despite challenges in nutrition and diagnostics.

Recent health news highlights various topics including Abbott's profit rise due to medical device sales, Trump's IVF comments ...

Analyst Larry Biegelsen from Wells Fargo maintained a Buy rating on Abbott Laboratories (ABT – Research Report) and keeping the price ...

Q3 2024 Earnings Call Transcript October 16, 2024 Abbott Laboratories beats earnings expectations. Reported EPS is $1.21, ...

In a perspective article published in Science, Professor Jonathan Rivnay explores next-generation bioelectronic medication.

If a company's history and track record were good enough reasons to buy its shares, it'd be easy to make a case for investing ...

There are many reasons to own Abbott Laboratories (NYSE: ABT), but they all boil down to one thing: consistent market-beating returns.